CA-EXPERIAN
22.5.2024 12:01:30 CEST | Business Wire | Press release
As companies around the globe grapple with an accelerated pace of change and seek ways to optimize their businesses, Experian® is ushering in a new era of simplification, scalability and automation through the debut of new enhancements to its cloud-based Experian Ascend Technology Platform™. Now, Experian’s award-winning platform brings together software tools for analytics, credit decisioning and fraud into a single interface — simplifying the deployment of analytical models and enabling businesses to optimize their practices more frequently, achieving greater efficacy with lower investment of time and money.
Experian’s enhancements were unveiled to more than 500 business leaders during its annual Vision conference in Scottsdale, Ariz., and represent a significant evolution in streamlining business-to-business software solutions.
Why it matters:
- The world’s top technology companies have set the standard for seamless user experiences and integrations between software components through single sign-on, data portability, and sophisticated no-code or low-code functionality.
- Historically, this type of synchronized experience has been unattainable to many businesses, especially those in the financial services sector.
- Typically, organizations buy software solutions from many different vendors, leverage a variety of tools and applications across different cloud environments, and go through rigorous and time-consuming processes to stitch everything together.
- This fragmented approach stretches timelines unnecessarily, raises security concerns and creates operational challenges. It also increases costs and the likelihood of errors or downtime because such setups are only as strong as their weakest link, perpetually causing issues when any single component fails.
“IT services companies are increasingly delivering their software portfolios as pre-integrated platforms that deliver scale, efficiency, productivity,” said Raymond Pucci, IDC Research Director, Worldwide Lending Digital Strategies. “For lenders, enterprise architectures like Experian's Ascend Technology Platform can enable faster credit-decisioning velocity, higher loan quality, and stronger risk management, expanding customer relationships and increasing business growth.”
The updates to Experian’s platform represent a notable milestone — fueled by Experian’s significant investments in innovation over the last eight years as part of its modern cloud transformation.
“Our mission is to develop world-class software and support organizations around the world on their journeys toward more sophisticated fraud prevention, marketing and credit strategies,” said Alex Lintner, CEO, Experian Software Solutions. “The evolution of our platform reaffirms our commitment to drive innovation and empower businesses to thrive. Its capabilities are unmatched and represent a significant leap forward in lending technology, democratizing access to data in compliant ways while enabling lenders of all sizes to seamlessly validate their customers’ identities with confidence, help expand fair access to credit and offer awesome user and customer experiences.”
Experian’s global scalability
Experian’s platform is available now in regions including North America, Brazil and the United Kingdom. The enhanced platform is being leveraged by more than 1,500 clients globally, processing 14 million credit reports daily and billions of credit and fraud transactions per year. In North America alone, over 8,000 registered users from 80 clients access over 12 petabytes of data weekly for analytical purposes.
A simplified and scalable approach
The enhanced Experian Ascend Technology Platform now dramatically reduces time to install and offers streamlined access to many of Experian's award-winning integrated solutions and tools through a single sign-on and managed via a user-friendly dashboard.
The platform leverages generative AI and makes it easy for clients from organizations of varying sizes and experience levels to pivot between applications, automate processes, modernize operations and drive efficiency. In addition, existing clients using Experian solutions today can now easily add new capabilities through the platform to enhance business outcomes.
For example, Lendr, a specialized fintech offering contemporary financing solutions for small businesses, is harnessing the power of the platform to enhance competitiveness and informed decision-making.
“Utilizing Experian Ascend Technology Platform has significantly bolstered our agility and competitive edge, empowering us to execute more informed, data-driven credit decisions while substantially reducing our time to market,” remarked Daniel DeMeo, CEO of Lendr. “Experian’s platform helps deliver the scalability we need to be nimble, compete effectively and mitigate losses — ultimately helping us double our business over the past year.”
Additional key features and benefits of the platform include:
- Analytics and model development: Clients can easily access and harness Experian's proprietary credit and expanded data attributes with powerful analytical tools for insights and explainable model creation.
- Rapid model deployment: Build, test and deploy models from a single interface in days rather than months, streamlining processes and enhancing customer experiences.
- Automated decisioning and risk mitigation: Enables secure, automated decisions and risk mitigation across the customer lifecycle, ensuring efficient operations and improved outcomes.
- Fraud and identity verification: Experian’s platform stops fraudsters faster and streamlines consumer experiences via a suite of software services powered by advanced AI analytics and comprehensive data assets across digital identity, device intelligence, behavioral analytics and credit insights. It delivers unrivaled identity verification and fraud risk detection to enable businesses to grow revenue through seamless consumer experiences and reduce fraud loss exposure.
- Expertise through managed services: While the platform offers automation and low-code functionality, clients can also access Experian’s expertise and top talent through managed services, democratizing advanced analytics techniques for lenders regardless of their resources or analytics experience.
- Continuous monitoring and feedback: Receive continuous monitoring and feedback to adapt strategies in real time and stay ahead of evolving challenges.
- Unparalleled security: The platform is fortified with encryption, robust access controls and proactive threat detection — while maintaining high availability and Enterprise-grade performance.
For more information about Experian’s platform, please visit https://www.experian.com/business/products/ascend.
About Experian
Experian is a global data and technology company, powering opportunities for people and businesses around the world. We help to redefine lending practices, uncover and prevent fraud, simplify healthcare, deliver digital marketing solutions, and gain deeper insights into the automotive market, all using our unique combination of data, analytics and software. We also assist millions of people to realize their financial goals and help them to save time and money.
We operate across a range of markets, from financial services to healthcare, automotive, agrifinance, insurance, and many more industry segments.
We invest in talented people and new advanced technologies to unlock the power of data and innovate. As a FTSE 100 Index company listed on the London Stock Exchange (EXPN), we have a team of 22,500 people across 32 countries. Our corporate headquarters are in Dublin, Ireland. Learn more at experianplc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240522675866/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
